A Phase 2 Trial of Paxalisib Combined With a Ketogenic Diet and Metformin for Newly Diagnosed and Recurrent Glioblastoma
Latest Information Update: 21 Aug 2024
At a glance
- Drugs Metformin (Primary) ; Paxalisib (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 22 Sep 2023 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
- 22 Sep 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 28 Feb 2022 According to a Kazia Therapeutics media release, enrollment is expected to be completed in 2H 2023.